Celecoxib
- Generic Name
- Celecoxib
- Brand Names
- Celebrex, Elyxyb, Seglentis
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14F3N3O2S
- CAS Number
- 169590-42-5
- Unique Ingredient Identifier
- JCX84Q7J1L
- Background
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.
Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
- Indication
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea.
Celecoxib, in combination with tramadol, is indicated for the management of acute pain in adults severe enough to require an opioid analgesic and in whom alternative treatments are inadequate.
- Associated Conditions
- Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
- Associated Therapies
- -
Effect of a Multimodal Pain Regimen on Pain Control, Patient Satisfaction and Narcotic Use in Orthopaedic Trauma Patients
- Conditions
- Interventions
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Registration Number
- NCT02160301
- Locations
- 🇺🇸
UNC Chapel Hill Hospital, Chapel Hill, North Carolina, United States
αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
- First Posted Date
- 2014-05-30
- Last Posted Date
- 2020-07-20
- Lead Sponsor
- David Bartlett
- Target Recruit Count
- 64
- Registration Number
- NCT02151448
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Centre Oscar Lambret
- Target Recruit Count
- 20
- Registration Number
- NCT02115074
- Locations
- 🇫🇷
CHU Angers, Angers, France
🇫🇷Centre Hospitalier de Nancy, Vandoeuvre-les-Nancy, France
🇫🇷Centre Oscar Lambret, Lille, France
Decreasing Narcotics in Advanced Pelvic Surgery
- First Posted Date
- 2014-04-10
- Last Posted Date
- 2016-08-17
- Lead Sponsor
- Hartford Hospital
- Target Recruit Count
- 138
- Registration Number
- NCT02110719
- Locations
- 🇺🇸
Hartford Hosptial, Hartford, Connecticut, United States
Treatment of Severe Influenza A Infection
- Conditions
- Interventions
- First Posted Date
- 2014-04-09
- Last Posted Date
- 2019-10-21
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 107
- Registration Number
- NCT02108366
- Locations
- 🇭🇰
Ivan Hung, Hong Kong, Hong Kong
Celecoxib in Preventing the Damaging Effects of Sunburn in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-03-28
- Last Posted Date
- 2016-12-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT02099136
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
Celecoxib in Decreasing the Damaging Effects of Sunburn in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2016-12-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT02090933
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain
- Conditions
- Interventions
- First Posted Date
- 2014-03-12
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 80
- Registration Number
- NCT02084511
- Locations
- 🇮🇹
1320.13.39001 Boehringer Ingelheim Investigational Site, Verona, Italy
Condrosulf vs Celebrex vs Placebo in the Treatment of Knee OA
- Conditions
- Interventions
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- IBSA Institut Biochimique SA
- Target Recruit Count
- 604
- Registration Number
- NCT02079727
- Locations
- 🇨🇿
Interni a revmatologicka ordinace, Breclav, Czech Republic
🇧🇪Unité d'exploration du metabolism osseux, CHU, Polyclinique universitaires L-Brull, Liege, Belgium
🇵🇱Medica Pro Familia, Warszawa, Poland
Tramadol Versus Celecoxib for Reducing Pain in Outpatient Hysteroscopy
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2015-01-05
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 210
- Registration Number
- NCT02071303
- Locations
- 🇪🇬
Cairo University Hospitals, Cairo, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.